
FIGS (FIGS) is heading to Barclays’ 19th Annual Global Consumer Staples Conference in Boston on 8 September 2026, where CEO Trina Spear and CFO Sarah Oughtred are scheduled to outline the healthcare apparel specialist’s current priorities.
FIGS heads into the Barclays conference after a choppy few weeks, with the share price down 14.8% over the last 7 days and 9.25% over 30 days, yet still sitting on a 13.7% year to date share price gain and a 77.4% 1 year total shareholder return that suggests longer term momentum has been strong.
Scan beyond FIGS and see how other healthcare and consumer names with similar momentum and business models stack up in our curated list of 18 high quality undiscovered gems.
After a 1 year run that has rewarded FIGS shareholders and a sharp pullback in recent weeks, are buyers today leaning into more upside ahead, or paying up after the best of the move?
FIGS is priced at $12.95 against a narrative fair value of $14.39, which frames the Barclays appearance around a market that is assigning a discount to the story according to julio.
The company, on an absolute basis, is still growing well. Further, it has several growth levers, such as expanding its product range, entering new markets, and leaning into its “TEAMS” offering.
Want to understand why that fair value sits above today’s price? The narrative leans heavily on steady expansion, improving profitability, and a future earnings profile that assumes current momentum can be sustained.
Result: Fair Value of $14.39 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, FIGS faces some clear pressure points, including execution risk around its margin targets and the possibility that weaker economic conditions could affect its premium positioning.
Find out about the key risks to this FIGS narrative.
That 10% undervalued narrative sits awkwardly beside how FIGS is currently priced in the market. The stock trades on a P/E of 34.7x, while the US Luxury industry sits at 15.5x and peers average 16.8x, with a fair ratio estimate of 15.1x suggesting investors are already paying up for the story.
If the share price ever drifted closer to that 15.1x fair ratio, would sentiment still look as confident as it does today, or would the FIGS debate feel very different?
See what the numbers say about this price — find out in our valuation breakdown.
Sentiment around FIGS may look divided right now, so move quickly to review the rewards and data points for yourself before the next narrative forms. To see what current optimism is built on, take a closer look at the 3 key rewards
If you stop with FIGS, you risk missing other opportunities where the numbers, balance sheets, and business quality could line up even better for your goals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com